• Diagnosis​ Info ​and​ ​General​ ​Questions

  FT-4202 Shows Favorable Profiles in Phase 1 Trial of Healthy Volunteers

  Posted by MG Community Member on February 7, 2020 at 8:17 am

  

  FT-4202, FORMA Therapeutics’ experimental disease-modifying therapy for sickle cell disease, shows favorable safety and pharmacokinetic profiles. Read more about it here.

  What do you think of this therapy?

  MG Community Member replied 6 years, 1 month ago 0 Member · 0 Replies
• 0 Replies

Log In to Reply